Oxford Nanopore Technologies vs ChromaCode

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (54 vs 54)
Oxford Nanopore Technologies logo

Oxford Nanopore Technologies

GrowthLife Sciences & BioTech

Long-Read Sequencing

UK nanopore sequencing pioneer with portable MinION device; £223M FY2025 revenue (+24% constant currency). Clinical revenues up 60% as sequencing moves to point-of-care.

AI VisibilityBeta
Overall Score
C54
Category Rank
#24 of 198
AI Consensus
92%
Trend
stable
Per Platform
ChatGPT
59
Perplexity
56
Gemini
58

About

Oxford Nanopore Technologies (ONT) was spun out of the University of Oxford in 2005, commercializing a radically different sequencing approach: passing DNA strands through biological nanopore proteins embedded in a membrane and detecting characteristic ionic current changes to call bases in real time. This enables ultra-long reads (megabase scale), direct RNA sequencing, and epigenetic base modification detection without prior amplification.\n\nONT's product range spans from the palm-sized MinION (the world's first portable DNA sequencer) to the high-throughput PromethION 2 Solo and PromethION 48 platforms. These instruments have enabled field sequencing for infectious disease outbreak response (COVID-19, mpox, Ebola), real-time clinical microbiology, plant pathogen surveillance, and cancer genomics. The company reported £223 million in FY2025 revenue, representing 24% constant-currency growth, with clinical revenues up 60% and biopharma revenues up 30%.\n\nONT is publicly listed on the London Stock Exchange and holds approximately £300 million in cash. While accuracy has historically lagged Illumina and PacBio, successive chemistry improvements and the Kit14 chemistry have closed the gap for many applications. The company is expanding its presence in clinical diagnostics, with regulatory filings underway in key markets, and remains the benchmark for portable, real-time, and long-read sequencing.

Full profile
ChromaCode logo

ChromaCode

ChallengerLife Sciences & BioTech

Molecular Diagnostics

ChromaCode develops HDPCR technology enabling standard PCR instruments to run highly multiplexed molecular diagnostic assays for infectious disease, oncology, and genetic testing at lower cost.

AI VisibilityBeta
Overall Score
C54
Category Rank
#31 of 198
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
48
Perplexity
54
Gemini
52

About

ChromaCode is a molecular diagnostics company developing High-Definition PCR (HDPCR), a breakthrough multiplexing platform that dramatically expands the number of analytes detectable in a single PCR well using standard laboratory instruments. By combining proprietary chemistry with amplitude modulation, multi-spectral encoding, and cloud-based decoding software, HDPCR enables labs to run panels for infectious disease, oncology biomarkers, transplant monitoring, and prenatal testing without expensive new hardware.

Full profile

AI Visibility Head-to-Head

54
Overall Score
54
#24
Category Rank
#31
92
AI Consensus
80
stable
Trend
stable
59
ChatGPT
48
56
Perplexity
54
58
Gemini
52
57
Claude
57
56
Grok
54

Key Details

Category
Long-Read Sequencing
Molecular Diagnostics
Tier
Growth
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Oxford Nanopore Technologies
Long-Read Sequencing

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.